Cargando…

Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings

Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Steegen, Kim, van Zyl, Gert U., Claassen, Mathilda, Khan, Aabida, Pillay, Melendhran, Govender, Subitha, Bester, Phillip A., van Straaten, Johanna M., Kana, Vibha, Cutler, Ewaldé, Kalimashe, Monalisa N., Lebelo, Ramokone L., Moloi, Mokopi B. H., Hans, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340187/
https://www.ncbi.nlm.nih.gov/pubmed/37443603
http://dx.doi.org/10.3390/diagnostics13132209
_version_ 1785072018640601088
author Steegen, Kim
van Zyl, Gert U.
Claassen, Mathilda
Khan, Aabida
Pillay, Melendhran
Govender, Subitha
Bester, Phillip A.
van Straaten, Johanna M.
Kana, Vibha
Cutler, Ewaldé
Kalimashe, Monalisa N.
Lebelo, Ramokone L.
Moloi, Mokopi B. H.
Hans, Lucia
author_facet Steegen, Kim
van Zyl, Gert U.
Claassen, Mathilda
Khan, Aabida
Pillay, Melendhran
Govender, Subitha
Bester, Phillip A.
van Straaten, Johanna M.
Kana, Vibha
Cutler, Ewaldé
Kalimashe, Monalisa N.
Lebelo, Ramokone L.
Moloi, Mokopi B. H.
Hans, Lucia
author_sort Steegen, Kim
collection PubMed
description Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent regimens are tailored on a case-by-case basis, should resistance be detected. Although there is a disparity in access to HIVDR testing in high-income countries compared to low- and middle-income countries (LMICS), more LMICs have now included HIVDR testing for individual patient management in some groups of patients. In this review, we describe different strategies for surveillance as well as where HIVDR testing can be implemented for individual patient management. In addition, we briefly review available technologies for HIVDR testing in LMICs, including Sanger sequencing, next-generation sequencing, and some point-of-care options. Finally, we describe how South Africa has implemented HIVDR testing in the public sector.
format Online
Article
Text
id pubmed-10340187
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103401872023-07-14 Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings Steegen, Kim van Zyl, Gert U. Claassen, Mathilda Khan, Aabida Pillay, Melendhran Govender, Subitha Bester, Phillip A. van Straaten, Johanna M. Kana, Vibha Cutler, Ewaldé Kalimashe, Monalisa N. Lebelo, Ramokone L. Moloi, Mokopi B. H. Hans, Lucia Diagnostics (Basel) Review Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent regimens are tailored on a case-by-case basis, should resistance be detected. Although there is a disparity in access to HIVDR testing in high-income countries compared to low- and middle-income countries (LMICS), more LMICs have now included HIVDR testing for individual patient management in some groups of patients. In this review, we describe different strategies for surveillance as well as where HIVDR testing can be implemented for individual patient management. In addition, we briefly review available technologies for HIVDR testing in LMICs, including Sanger sequencing, next-generation sequencing, and some point-of-care options. Finally, we describe how South Africa has implemented HIVDR testing in the public sector. MDPI 2023-06-29 /pmc/articles/PMC10340187/ /pubmed/37443603 http://dx.doi.org/10.3390/diagnostics13132209 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Steegen, Kim
van Zyl, Gert U.
Claassen, Mathilda
Khan, Aabida
Pillay, Melendhran
Govender, Subitha
Bester, Phillip A.
van Straaten, Johanna M.
Kana, Vibha
Cutler, Ewaldé
Kalimashe, Monalisa N.
Lebelo, Ramokone L.
Moloi, Mokopi B. H.
Hans, Lucia
Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
title Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
title_full Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
title_fullStr Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
title_full_unstemmed Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
title_short Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
title_sort advancing hiv drug resistance technologies and strategies: insights from south africa’s experience and future directions for resource-limited settings
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340187/
https://www.ncbi.nlm.nih.gov/pubmed/37443603
http://dx.doi.org/10.3390/diagnostics13132209
work_keys_str_mv AT steegenkim advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT vanzylgertu advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT claassenmathilda advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT khanaabida advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT pillaymelendhran advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT govendersubitha advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT besterphillipa advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT vanstraatenjohannam advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT kanavibha advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT cutlerewalde advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT kalimashemonalisan advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT lebeloramokonel advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT moloimokopibh advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings
AT hanslucia advancinghivdrugresistancetechnologiesandstrategiesinsightsfromsouthafricasexperienceandfuturedirectionsforresourcelimitedsettings